Influence of basiliximab and on recipients'interleukin-2 and soluble interleukin-2 receptor after renal transplantation

AIM: To analyze the influence of basiliximb and anti-CD 3 monoclonal antibody (OKT3) on renal transplant recipients' interleukin-2(IL-2) and soluble interleukin-2 receptor (sIL-2R) by basiliximab and evaluate the efficacy and safety of basiliximab and OKT3. METHODS: Seventy-four recipients were divided into basiliximab group(n=39) and OKT3 group (n=35). All recipients were taken triple immunosuppressive therapy with steroids, mycophenolate mofetil and cyclosporine. Basiliximab group received basiliximab(20 mg) iv, drip 2 h before operation and d 4 postoperation. OKT3 group received OKT3 (5 mg·d -1) iv, drip from postoperative d 1 for 7 or 10 d. The concentrations of IL-2 and sIL-2R at different time points in 2 mo after transplantation were detected. Acute rejection, renal function, adverse reactions and survival rates of grafts and recipients within 2 mo after transplantation were observed. RESULTS: The concentration of IL-2 and sIL-2R in basiliximab group was significantly lower than that in OKT3 group(P 0.05). During a follow-up 2 mo 3 patients were subjected to acute rejection(AR) in basiliximab group and 9 in OKT3 group(P 0.05).The time of recovery of renal function in basiliximab group(4.7±s 2.1) d was earlier than that in OKT3 group (9±5) d (P 0.05). The incidences of infection, cytokine release syndrome and allergic reaction in basiliximab group were significantly lower than those in OKT3 group(P 0.05). CONCLUSION: Basiliximab is a safe and effective induction therapeutic agent and can significantly reduce the concentration of IL-2 and sIL-2R, occurrence rate of AR.